Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous tocilizumab in rheumatoid arthritis as monotherapy or with non-biologic DMARDs
2013-002429-52Phase 3Completed
- Sponsor
- Roche
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of tocilizumab in rheumatoid arthritis (RA) (5 arms), sponsored by Roche. Primary endpoint: Proportion of patients achieving sustained clinical remission at week 24. Started Jul 2013; status: completed.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2013-002429-52.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002429-52.